Opus Genetics (IRD) Net Margin (2010 - 2026)
Opus Genetics (IRD) posted quarterly Net Margin of 3038.25% for Q1 2026, down 285074.0% year-over-year from N/an in Q1 2025, and down 1822.22% quarter-over-quarter from 158.06% in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Net Margin (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Net Margin for 8 consecutive years, with 3038.25% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 285074.0% year-over-year to 3038.25%; the TTM figure through Mar 2026 stood at 805.46% (down 37604.0% YoY), while the FY2025 annual figure was 275.97%, up 24743.0% from the prior year.
- Net Margin fell to 3038.25% in Q1 2026 per IRD's latest filing, from 158.06% in the prior quarter.
- Across five years, Net Margin topped out at 85.17% in Q4 2022 and bottomed at 3038.25% in Q1 2026.
- Historically, Net Margin has averaged 496.5% across 5 years, with a median of 270.51% in 2025.
- Annual changes were most pronounced in 2025 — Net Margin jumped 65865 bps — and 2026, when it tumbled 285074 bps.
- Opus Genetics' Net Margin stood at 85.17% in 2022, then sank by 433 bps to 283.56% in 2023, then sank by 188 bps to 816.71% in 2024, then surged by 81 bps to 158.06% in 2025, then tumbled by 1822 bps to 3038.25% in 2026.
- Business Quant data shows IRD's Net Margin at 3038.25% in Q1 2026, 158.06% in Q4 2025, and 566.87% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -1,072.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,072.58% |
| Mar 31, 2026 | -3,038.25% |
| Dec 31, 2025 | -158.06% |
| Sep 30, 2025 | -566.87% |
| Jun 30, 2025 | -257.46% |
| Mar 31, 2025 | -187.51% |
| Dec 31, 2024 | -816.71% |
| Sep 30, 2024 | -194.62% |
| Jun 30, 2024 | -698.29% |
| Mar 31, 2024 | -415.31% |
| Dec 31, 2023 | -283.56% |
| Sep 30, 2023 | 46.59% |
| Jun 30, 2023 | -135.03% |
| Mar 31, 2023 | -331.10% |
| Dec 31, 2022 | 85.17% |
| Sep 30, 2021 | -865.03% |
| Jun 30, 2021 | -7,136.00% |
| Mar 31, 2020 | -268.52% |
| Jun 30, 2010 | -19,184.37% |